Collegium Pharmaceutical (NASDAQ:COLL) Announces Quarterly Earnings Results

Collegium Pharmaceutical (NASDAQ:COLL) announced its earnings results on Thursday. The specialty pharmaceutical company reported $2.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.89 by $0.36, Briefing.com reports. Collegium Pharmaceutical had a net margin of 7.72% and a return on equity of 102.03%. The company had revenue of $209.36 million during the quarter, compared to analysts’ expectations of $191.25 million. During the same quarter in the previous year, the business posted $1.61 earnings per share. The firm’s quarterly revenue was down 18.9% compared to the same quarter last year. Collegium Pharmaceutical updated its FY 2025 guidance to EPS and its FY 2025 guidance to EPS.

Collegium Pharmaceutical Price Performance

Collegium Pharmaceutical stock traded up $1.64 during trading hours on Friday, hitting $42.30. 864,974 shares of the company traded hands, compared to its average volume of 414,440. Collegium Pharmaceutical has a 1-year low of $23.23 and a 1-year high of $43.06. The company has a quick ratio of 1.10, a current ratio of 1.54 and a debt-to-equity ratio of 2.94. The firm has a market cap of $1.33 billion, a P/E ratio of 26.27 and a beta of 0.61. The firm’s 50-day simple moving average is $35.70 and its two-hundred day simple moving average is $32.80.

Insider Buying and Selling at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, Director Gino Santini sold 5,405 shares of the business’s stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $37.19, for a total value of $201,011.95. Following the sale, the director directly owned 95,042 shares in the company, valued at approximately $3,534,611.98. The trade was a 5.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Thomas B. Smith sold 17,478 shares of the stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $38.42, for a total transaction of $671,504.76. Following the sale, the executive vice president directly owned 70,264 shares of the company’s stock, valued at approximately $2,699,542.88. This represents a 19.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 74,133 shares of company stock valued at $2,899,504 in the last ninety days. 2.51% of the stock is owned by insiders.

Hedge Funds Weigh In On Collegium Pharmaceutical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Engineers Gate Manager LP boosted its position in shares of Collegium Pharmaceutical by 165.7% in the second quarter. Engineers Gate Manager LP now owns 70,077 shares of the specialty pharmaceutical company’s stock worth $2,072,000 after buying an additional 43,705 shares during the period. PDT Partners LLC acquired a new position in Collegium Pharmaceutical in the second quarter worth approximately $425,000. Qube Research & Technologies Ltd raised its holdings in shares of Collegium Pharmaceutical by 77.1% during the 2nd quarter. Qube Research & Technologies Ltd now owns 94,880 shares of the specialty pharmaceutical company’s stock valued at $2,806,000 after purchasing an additional 41,315 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Collegium Pharmaceutical by 3.7% during the second quarter. JPMorgan Chase & Co. now owns 72,068 shares of the specialty pharmaceutical company’s stock valued at $2,131,000 after buying an additional 2,592 shares in the last quarter. Finally, Jane Street Group LLC raised its stake in shares of Collegium Pharmaceutical by 218.7% in the 1st quarter. Jane Street Group LLC now owns 131,520 shares of the specialty pharmaceutical company’s stock valued at $3,926,000 after acquiring an additional 90,255 shares in the last quarter.

Analyst Ratings Changes

COLL has been the topic of several recent analyst reports. Needham & Company LLC reissued a “buy” rating and set a $46.00 price objective on shares of Collegium Pharmaceutical in a research note on Tuesday, October 28th. Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday. HC Wainwright boosted their price target on Collegium Pharmaceutical from $44.00 to $46.00 and gave the stock a “buy” rating in a research report on Friday. Weiss Ratings reissued a “hold (c)” rating on shares of Collegium Pharmaceutical in a research report on Wednesday, October 8th. Finally, Zacks Research downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 23rd. Three research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, Collegium Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average target price of $44.25.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.